Artiva Biotherapeutics (ARTV) Accumulated Depreciation & Amortization (2023 - 2025)
Artiva Biotherapeutics (ARTV) has disclosed Accumulated Depreciation & Amortization for 3 consecutive years, with $8.5 million as the latest value for Q4 2025.
- On a quarterly basis, Accumulated Depreciation & Amortization rose 42.78% to $8.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.5 million, a 42.78% increase, with the full-year FY2025 number at $8.5 million, up 42.78% from a year prior.
- Accumulated Depreciation & Amortization was $8.5 million for Q4 2025 at Artiva Biotherapeutics, up from $7.2 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $8.5 million in Q4 2025 to a low of $1.1 million in Q2 2023.
- A 3-year average of $4.9 million and a median of $5.6 million in 2024 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: grew 6.63% in 2024, then skyrocketed 501.85% in 2025.
- Artiva Biotherapeutics' Accumulated Depreciation & Amortization stood at $3.5 million in 2023, then skyrocketed by 67.7% to $5.9 million in 2024, then soared by 42.78% to $8.5 million in 2025.
- Per Business Quant, the three most recent readings for ARTV's Accumulated Depreciation & Amortization are $8.5 million (Q4 2025), $7.2 million (Q2 2025), and $6.5 million (Q1 2025).